Robin Knifsend News Today : Breaking News, Live Updates & Top Stories | Vimarsana

From Politics To Industry Reputation Top Of Mind Topics For Execs In Biopharma

From trade relations to industry reputations, five biopharmaceutical executives share their thoughts on top-of-mind topics as we ready for 2022 and.

Ivan dimovXalud therapeuticsdiem nguyenPeter marianiSynthekinerobin knifsendRob wrightBioivan dimovDiem nguyenAxogenpeter marianiRobin knifsendEyepoint pharmaceuticalsUs political affairsChief editorLife scienceOrca bioivan dimovOrca bioLife science leader

What s The Biopharma Financial View For 2022

Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

New yorkUnited statesOlivia tyrrellPeter marianiParag shahSamir gharibRob wrightTroy ignelziRobin knifsendIvor macleodBaker mckenzieHealth venturesChief editorLife scienceSpruce biosciencesBig data

BioSpace Movers & Shakers, June 4

Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

Wills eye hospitalUnited statesM karen newell rogersMyers squibbDenise straussMarc semigranDavidc hanleyEric castaldiJen hongMeagher flomMarc massiotNewell rogersRobin knifsendTheodore reissJeff cruikshankEvelo biosciences

Stanford spinout Synthekine raises $107 5M on promise of new way to attack cancer, autoimmune diseases

Stanford spinout Synthekine raises $107 5M on promise of new way to attack cancer, autoimmune diseases
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

United statesMenlo parkStanford universityRock springsSan franciscoChris garciaRon leutyPatrick lupardusNaiyer rizviDebanjan rayRobin knifsendLaurene powell jobsRob kasteleinActerlion pharmaceuticalsPortola pharmaceuticals incMerck co

Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Mardi Dier to its board of directors, Robin Knifsend as senior vice president of finance and operations and Antoni Ribas, M.D., Ph.D., to its scientific advisory board.

Antoni ribasAlexion pharmaceuticalsPortola pharmaceuticalsRobin knifsendScientific advisory boardUltragenyx pharmaceuticalSenior vice presidentStanford universityJanssen pharmaceuticalsSynthekine incBoard of directorsஅன்டோனி ரிபாஸ்